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Only a single drug against schistosomiasis is currently available and new drug development
is urgently required but very few drug targets have been validated and characterised. How-
ever, regulatory systems including cyclic nucleotide metabolism are emerging as primary
candidates for drug discovery. Here, we report the cloning of ten cyclic nucleotide phospho-
diesterase (PDE) genes of S. mansoni, out of a total of 11 identified in its genome. We clas-
sify these PDEs by homology to human PDEs. Male worms displayed higher expression
levels for all PDEs, in mature and juvenile worms, and schistosomula. Several functional
complementation approaches were used to characterise these genes. We constructed a
Trypanosoma brucei cell line in which expression of a cAMP-degrading PDE complements
the deletion of TbrPDEB1/B2. Inhibitor screens of these cells expressing only either
SmPDE4A, TbrPDEB1 or TbrPDEB2, identified highly potent inhibitors of the S. mansoni
enzyme that elevated the cellular cAMP concentration. We further expressed most of the
cloned SmPDEs in two pde1Δ/pde2Δ strains of Saccharomyces cerevisiae and some also
in a specialised strain of Schizosacharomyces pombe. Five PDEs, SmPDE1, SmPDE4A,
SmPDE8, SmPDE9A and SmPDE11 successfully complemented the S. cerevisiae strains,
and SmPDE7var also complemented to a lesser degree, in liquid culture. SmPDE4A,
SmPDE8 and SmPDE11 were further assessed in S. pombe for hydrolysis of cAMP and
cGMP; SmPDE11 displayed considerable preferrence for cGMP over cAMP. These results
and tools enable the pursuit of a rigorous drug discovery program based on inhibitors of S.
mansoni PDEs.
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Author summary
Schistosomiasis is a serious and often fatal disease that is caused by infection with parasitic
worms of the Schistosoma species. It affects several hundreds of millions of people world-
wide, mostly in the tropics, through contact of skin with infected water, usually lakes and
rivers. Only one drug, praziquantel, exists for its treatment, so resistance to it would leave
the disease untreatable and new drugs are urgently needed. Here, we report on a strategy
to develop new anti-schistosomal agents by inhibiting the regulatory systems of the worm.
Cyclic nucleotides cAMP and cGMP are key regulators of cellular activity, and their activ-
ity is determined by enzymes called phosphodiesterases or PDEs, that can degrade them.
We identified and cloned the genes coding for ten of these PDEs from Schistosoma man-
soni, a species causing a very high disease burden. By expressing these genes in specialized
cell lines of the yeast Saccharomyces cerevisiae and the protozoan parasite Trypanosoma
brucei, under conditions where growth becomes conditional on the expression of the
introduced Schistosoma PDE, we show that most of these genes indeed code for functional
PDEs. For several PDEs we also determined, using a third expression system, the yeast
Schizosaccharomyces pombe, whether they regulate cAMP or cGMP. We also identify a
number of inhibitors for one of these PDEs and show that all are expressed more in male
than in female worms. This work is essential to map and characterise the regulatory path-
ways of schistosomes and will facilitate the development of inhibitors of the key enzymes.
Introduction
Schistosomiasis is caused by parasitic trematodes of the genus Schistosoma. Theodor Bilharz
first reported on the causes of urinary schistosomiasis in 1851 and the life cycle was described
in the early years of the 20th century [1]. One hundred anf fifty years later, it is still a significant
disease burden. The transmission cycle includes contact with infected water and is relatively
easy to interrupt through proper sanitation, and control of the intermediary host, freshwater
snails of the family Planorbidae [2, 3]. Yet, according to the most recent figures of the WHO,
at least 220 million people are infected with these blood flukes and as 20 million people suffer
severe consequences as a result of advanced schistosomiasis, including an estimated 200,000
annual deaths as of 2000 [4], although this should by now have reduced substantially.
Currently the only available drug against schistosomiasis is praziquantel (PZQ) [5], first
introduced in the late 1970s [6]. It is considered to be an effective treatment with single-dose
activity against all human-infective schistosomes [7]. However, the treatment does have some
limitations, including inactivity against juvenile worms, i.e. recent infections, and, in many
patients, incomplete clearance of the infection [5, 8, 9]. In addition, there are multiple reports
that some level of PZQ resistance may already exist in the field [10, 11], due to repeated mass
administration programs [12]. It would be potentially catastrophic to lose the only treatment
for this fatal disease, which is already killing hundreds of thousands of people [13, 14]. How-
ever, there is currently hardly even the beginning of a drug-discovery pipeline for
schistosomiasis.
It is thus clear that the development of additional treatment options is urgent. One promis-
ing avenue for antischistosomal drug discovery is to target the trematode’s regulatory systems,
such as receptors, ion channels, and signal transduction mechanisms. These are sufficiently
different from human systems to have a potentially different inhibitor profile, yet are suffi-
ciently conserved to be recognizable in the genome and to be susceptible to repurposing of
existing compound classes. One such example is PZQ itself, which is believed to target
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Schistosoma calcium channels (Doenhoff et al., 2008), and a number of studies have started the
characterization of key Schistosoma G-protein coupled receptors [15–20]. Of particular inter-
est are serotonin receptors that are widely distributed in the schistosomal nervous system and
induce elevated levels of cellular cAMP when stimulated [17], and for which a distinct pharma-
cology has started to emerge [19, 20].
The cyclic nucleotides cAMP and cGMP are key regulators in schistosomes. As early as
1973, strong activities of adenylate cyclase, cAMP and cGMP phosphodiesterases (PDEs) and
cyclic nucleotide-stimulated protein kinases were identified and some inhibitors of these
enzymes were identified—indeed, serotonin was shown to stimulate the adenylate cyclase
activity in S. mansoni [21]. However, until recently little progress was made in understanding
the various roles of cAMP in schistosome physiology, or in characterizing any of the cAMP
pathway components. Taft and coworkers showed that, as in many protozoa [22, 23], a key life
cycle progression in S. mansoni, from miracidium to primary sporocyst, was coupled to regula-
tion via cAMP [24]. A cAMP-activated kinase, PKA, was identified, cloned and found to be
essential for schistosome survival, using both inhibitors and RNAi knockdown [25]. PKA was
found to have an important role in regulating motor activity, with its stimulation resulting in
hypermotility of the adult worms [26]. Similarly, Hirst et al. also found that PKA modulated
motility in cercariae and schistosomula [27].
The essentiality of the cAMP signaling pathways, including PKA, prompted us to extend
our work on cAMP phosphodiesterases of protozoan parasites [28–32] to S. mansoni, antici-
pating that, as in human-infective protozoa, inhibition of PDEs leads to a fatal increase and
imbalance in cellular cAMP levels. Indeed, Caffrey and co-workers recently reported the clon-
ing of several homologues of human PDE4 isoforms, and identified benzoxaborole inhibitors
of these enzymes that induced hypermotility in the worms [33]. Moreover, the screening of a
small library of potential PDE inhibitors identified numerous hits with activity on worm via-
bility and/or ovipositing in vitro as well as reduced worm and egg burdens in a mouse model
of S. mansoni infection [34].
Here, we analyze the S. mansoni genome for all PDE sequences, classify and name them
according to phylogenetic analysis. We report the cloning and sequence verification of 10 of
the 11 SmPDEs thus identified and present evidence from functional complementation in dif-
ferent yeast and protozoan systems that most of these are indeed cyclic nucleotide phosphodi-
esterases; their relative expression in male and female mature and juvenile worms as well as
schistosomula was also determined. By complementation of a Trypanosoma brucei cell line
lacking the essential PDEB1/B2 locus, a cellular system for inhibitor screening of SmPDEs was
established, and potent new inhibitors of SmPDE4A were identified.
Results
SmPDE amplification and naming
Our searches of the published S. mansoni genome suggested there was a complement of eleven
PDE-encoding genes in this species. Four of these have been described previously as being
homologous to human PDE4 [33]. Of the eleven sequences, we have successfully amplified ten
of the full coding sequences from adult worm cDNA of Egyptian strain CD (see WormBase
ParaSite 14 IDs and GenBank accession numbers in Table 1).
A phylogenetic tree was constructed using MEGA6 to analyze the relationship of the
SmPDEs to representative members of the human PDE families, in order to derive a systematic
naming convention (Fig 1A, Table 1). Our in-house sequence information was used for the
ten available genes, with the genomic sequence used for the remaining one (SmPDE2). Three
PDEs clustered with hPDE4B1 and were previously identified by the group of Conor Caffrey,
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using the available genomic sequence from a Puerto Rican S. mansoni isolate available in Gen-
eDB [33], so we have maintained the naming convention of SmPDE4A-C for these genes. Our
sequences for the PDEs differed from those adopted by the Caffrey group. Of note is that our
sequence for SmPDE4A was 73 amino acids longer than the sequence previously reported
[33], although there were only two SNPs over the length of the reported sequence; the differ-
ence being a single 219 bp insert after position 649. Our sequence of SmPDE4B was of equal
Table 1. Systematic naming of SmPDEs.
Gene ID PDE4NPD Name Allele or splice variant Length (bp, aa) GenBank accession number
Smp_134500 Sm1 sv1 1815; 605 MH457507
sv2 1818; 606 MH457508
Smp_135500 Sm2 (genome) 877 none
Smp_134140 Sm4A 2097; 699 MH457509
Smp_141980 Sm4B a1 3066; 1022 MH457510
a2 3060; 1020 MH457511
Smp_334600 Sm4C 2109; 703 MN442427
Smp_153640 Sm7var a1 2058; 686 MH457512
a2 2058; 686 MH457513
Smp_044060 Sm8 1668; 555 MH457514
Smp_197150 Sm9A 1554; 517 MH457515
Smp_146120 Sm9B a1 2751; 917 MH457516
a2 2745; 915 MT655752
Smp_342020 Sm9C 1923; 641 MH457517
Smp_179590 Sm11 1 3243; 1081 MH457518
2 3243; 1081 MH457519
a, allele; sv, splice variant.
https://doi.org/10.1371/journal.pntd.0008447.t001
Fig 1. Overview of PDE family genes of Schistosoma mansoni. A. Phylogenetic tree comparing full length sequences
of all SmPDEs to representative members of the human PDE families. Human sequences were taken from Uniprot
database, the S. mansoni genes were from in-house sequencing, unless “gen” is included in the name as this gene is as
listed in the S. mansoni genome (taken from WormBase ParaSite 14). Black = S. mansoni; red = human. The tree was
constructed using a ClustalW alignment [94] and the Maximum Likelihood Tree function of MEGA6, with 500
bootstrap replications, the Nearest-Neighbor-Interchange (NNI) Heuristic Method, and otherwise the default
parameters. The percentage of trees in which the associated taxa clustered together is shown next to the branches. The
scale bar represents the number of amino acid substitutions per position. B. Overview of domain structure of each of
the S. mansoni PDE genes, using the genetic information from the successfully amplified cDNAs where available, or
the genomic sequence from WormBase ParaSite 14 (for SmPDE2) where amplification from cDNA had not been
successful. Significant inserts in the catalytic domain (compared to mammalian consensus sequence) are indicated by
hatched areas. Start and end of the catalytic domain is indicated by amino acid numbering. FL, full length.
https://doi.org/10.1371/journal.pntd.0008447.g001
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length with the reported one, and 99% identical at the nucleotide level, whereas their sequence
of SmPDE4C (Smp_129270) contained a different first exon and lacked what is exon 4 in the
new WormBase ParaSite 14 (WBPS14) sequence (Smp_334600.1e4) and our experimentally
obtained sequence, which, as a consequence is much longer than Smp_129270 (703 vs 454 aa,
respectively).
The gene previously identified as SmPDE4D [33] clustered separately with hPDE8B and we
therefore propose this gene to be renamed as SmPDE8. We found an unannotated exon
between the annotated exons 1 and 2, and that the actual start codon was 50 aa upstream from
the originally proposed start codon, giving rise to a protein of 555 aa compared to 482 aa pro-
posed previously.
We also found three genes that cluster with hPDE9A, and have named these SmPDE9A-C.
One SmPDE clustered with hPDE1C, and has thus been named SmPDE1; one, clustering with
hPDE2A3, was designated SmPDE2 but amplification from cDNA of our S. mansoni strain
CD was unsuccessful. The remaining two genes did not clearly cluster with any of the human
PDE sequences, and we therefore identified previously named homologues to maintain a logi-
cal naming convention. Using protein-protein BLAST searches we assigned the names of
SmPDE11 and SmPDE7var, with the family-number assigned based on the top hits of S. hae-
matobium PDEs—“dual 3’,5’-cyclic-AMP and-GMP phosphodiesterase 11” (MS3_05265) for
SmPDE11 and “high affinity cAMP-specific 3’,5’-cyclic phosphodiesterase 7A” (MS3_06540)
for SmPDE7var. SmPDE7var was so named as it appears to be more closely related to PDE7s
than to anything else, but it is clearly unusual based on the phylogenetic analysis. The “variant”
name is analogous to that used for calcium channel β subunits in S. mansoni [35].
Despite extensive work, it was not possible to amplify the coding regions of the single
remaining SmPDE, SmPDE2, from mammalian lifecycle stage cDNA (schistosomula, juvenile
male/female worms or adult male/female worms). Using genomic DNA, it was possible to
amplify a fragment of the 5’ UTR extending into the first exon of SmPDE2 (which was identi-
cal to published genome sequence), and from the 3’ UTR to the last exon, suggesting the gene
could be present and expressed in different lifecycle stages for which we did not have cDNA
available. Additionally, it may be that the sequence is quite different in strain CD compared to
the genomic Puerto Rican NMRI strain, as we were not able to amplify any of the other pre-
dicted exons in the middle of the gene from gDNA. Efforts to amplify this gene from cDNA
obtained from S. mansoni CD cercariae are ongoing.
Analysis of the SmPDE sequences
For most SmPDEs that were successfully sequenced we found differences to the genomic
sequences given in WBPS14; most of these changes were outside the predicted catalytic
domain. All changes relative to the genome sequences are summarized in Table 2, illustrated
with alignments to the genome sequences in S1 Fig, summarized schematically in Fig 1B, and
discussed below. Following the initial identification of S. mansoni PDEs both sequence and
predicted structure alignments were used to validate intron and exon boundaries to define the
PDE catalytic domains.
One allele was found for SmPDE1 (Smp_134500), but with a minor splice variation causing
a difference of a single glutamine residue at the start of predicted exon 7, inside the catalytic
domain (NAGNAG wobble splicing [36]). Both of the splice variants (SmPDE1-sv1 and
SmPDE1-sv2) are found in WBPS14, as Smp_134500.1 and Smp_134500.2. From the sequenc-
ing traces we concluded that the longer variant (SmPDE1-sv2) is more highly expressed, in
agreement with the preferrence in simalar human splice sites [36]. Both TDR targets (tdrtar-
gets.org) and GeneDB (genedb.org) list this gene product as a calcium:calmodulin (CaM)-
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dependent cyclic nucleotide phosphodiesterase and a CaM binding domain was found near
the N-terminal end (Fig 1B).
For SmPDE4A only one allelic sequence was found. The sequence coding for the PDE is
identical to that of the reference genome entry Smp_134140. However, splicing of the identi-
fied transcript differs from all the variants annotated in the WormBase/ParaSite database. The
first exon is located more than 26 kb upstream of the predicted start of the gene locus, giving it
a unique N-terminal sequence (S1 Fig). All other exons are found in at least one of the five
database variants, e.g. exons 2–10 are identical with those of variant Smp_134140.5 and the
rest with variant Smp_134140.1. Four of the predicted variants (Smp_134140.2 to 5) lack cru-
cial parts of the catalytic domain. As discussed by Long et al. [33] this gene (and SmPDE4B)
contains two Upstream Conserved Domains (UCRs) (Fig 1B), which are usually involved in
dimerisation.
There were two alleles for SmPDE4B, SmPDE4B-a1 and SmPDE4B-a2, each containing the
UCR1 and UCR2 domains (Fig 1B), with minimal changes compared to each other, or to the
Table 2. Coding sequences differences between predicted genome sequence from WormBase ParaSite 14 and
sequence obtained from cDNA from Cairo strain CD of S. mansoni.
Gene Size Differences found in CDS from genome
Sm1 605/606 aa One allele found, but with a small splice variant–one has a glutamine inserted at start
of exon 8, inside the catalytic domain. Both wobble splice variants exist in WBPS14,
as Smp_134500.1 and Smp_134500.1.
Sm2 833 or 965 aa
(genome)
Amplification unsuccessful from cDNA from the developmental stages available.
WBPS14 ID is Smp_135500.1 and Smp_135500.2.
Sm4A 699 aa 1 allele found, sequence identical to WBPS14 except for splice variations: a small
exon 1 in our sequence is located >26kb upstream of the predicted sequence. All
other exons are found in at least 1 of the reported transcripts Smp_134140.1 –
Smp_134140.5.
Sm4B 1022 / 1020 aa Two alleles found. Allele SmPDE4B-1 is identical to Smp_141980.1. SmPDE4B-2 is
different only by replacing 585-Ile-Asn-Ser in exon 4 with 585-Cys, resulting in the
shortening of the sequence by two aa.
Sm4C 703 aa 1 allele found. The deduced amino acid sequence differs from the single variant in
WBPS14 (Smp_334600) at three positions: two SNPs in the N-terminal regulatory
domain and a short glutamic acid stretch adjoining the catalytic domain varies in
length by 1 residue.
Sm7var 686 aa Two alleles found. We found, compared to the reference genome (Smp_153640.2),
one heterozygous and two homozygous single nucleotide substitutions, all non-
synonymous and outside the catalytic domain. Unusually, the catalytic domain is
predicted to be towards the N-terminal half of this PDE, alone amongst the SmPDEs.
Sm8 555 aa One allele found, 270 amino acids shorter than the WBPS14 entry (Smp_044060).
Amino acid residues 48–55 differ from the database entry due to an extended exon 7,
which fully replaces the predicted exon Smp_044060.1.e8. This difference is outside
the catalytic domain.
Sm9A 517 aa One allele found, different by two synonymous substitutions from Smp_197150.1.
Sm9B 917 / 915 aa Two alleles found, one identical to Smp_146120.1, in the other three residues of a
stretch of Asp residues have been replaced by one Thr residue.
Sm9C 641 aa We found one allele. Significant differences from its WBPS14 entry (Smp_342020.1
and 2): extra N-term Met residue; lacking an Ile-rich 23 aa stretch found in both
reference alleles (position 201) that is predicted to disrupt helix 6 of the catalytic
domain; unusual 159 aa insert in the catalytic domain, predicted to be located in the
loop between helices 12 and 13; exon 8 is extended compared to the exons
Smp_342020.1.e8 and 2.e8 of the database variants leading to a shorter and different
C-terminus as exon Smp_342020.1.e9 is not used.
Sm11 1081 a.a. Two allelic isoforms found, differing by 4 amino acids (non-synonymous SNPs)
outside the catalytic domain; allele SmPDE11-a1 is identical with the database
variant Smp_179590.1 at CDS and aa level.
https://doi.org/10.1371/journal.pntd.0008447.t002
PLOS NEGLECTED TROPICAL DISEASES Functional complementation of S. mansoni phosphodiesterases
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008447 July 30, 2020 6 / 29
genome reference Smp_141980. Isoform SmPDE4B-a1 is identical to Smp_141980.1;
SmPDE4B-a2 contains one Cys residue rather than the sequence Ile-Asn-Ser in exon 4 (S1
Fig), which is not in the catalytic domain.
We found one allele for SmPDE4C. The deduced amino acid sequence differs from the sin-
gle variant in the WBPS14 database, Smp_334600.1, at three positions: two residues are substi-
tuted in the N-terminal regulatory domain and a short glutamic acid stretch adjoining the
catalytic domain varies in length by 1 residue (S1 Fig). We found one potential UCR domain,
between amino acids 81 and 185 (Fig 1B).
There were again two alleles of SmPDE7var found. SmPDE7var-a1 is identical to
Smp_153640.2 except for two non-synonymous SNPs near the C-terminal end; SmPDE7var-
a1 contains one additional non-synonymous SNP, at position 478 (S1 Fig). None of these sub-
stitutions are located in the catalytic domain, which, unusually, is predicted to be towards the
N-terminal half of this PDE–unique amongst the SmPDEs (Fig 1B); no GAF, CaM or UCR
domains were identified.
For SmPDE8 only one allele was found. The N-terminus was found to be 270 amino acids
shorter than of the single predicted variant in the WBPS14 database, Smp_044060.1. Amino
acid residues 48–55 differ from the database entry due to an extended exon 7, which fully
replaces the predicted exon Smp_044060.1.e8. This difference is outside the catalytic domain.
However, as was previously described [33], SmPDE8 (both the reference and our experimental
sequence) has an unusual insertion in its catalytic domain, which, when compared to hPDE8
rather than hPDE4, results in a 31 aa insertion, with a conserved cysteine residue in the middle
of the insertion (S1 Fig; Fig 1B).
One allele of SmPDE9A was found, differing from the single database entry
(Smp_197150.1) in two synonymous nucleotide substitutions located in exons 4 and 14. The
deduced amino acid sequences are therefore identical. Another sequence was amplified from
the cDNA, which included an additional exon between exons 5 and 6; however, this insertion
introduces a frameshift and a premature stop codon after 194 aa; well before the start of the
catalytic domain around 255 aa. For SmPDE9B we found two alleles, one identical to
Smp_146120.1, in the other three residues of a stretch of Asp residues have been replaced by
one Thr residue.
A single allele was also found for SmPDE9C, which was significantly different from the
genome sequence (Smp_342020.1 and 2). Our sequence contained an extra N-terminal methi-
onine residue and lacked an Ile-rich 23 aa stretch found in both reference alleles (position 201)
that is predicted to disrupt helix 6 of the catalytic domain and could make the reference pro-
tein non-functional. Our sequence and both reference alleles also contained an unusual 156 aa
insert in the catalytic domain, compared to hPDE9A. The insert is predicted to be located in
the loop between helices 12 and 13 and is itself predicted to contain 7 alpha helices. In our
sequence of SmPDE9C exon 8 was extended compared to the exons Smp_342020.1.e8 and 2.
e8 of WBPS14, leading to a shorter and different C-terminus as exon Smp_342020.1.e9 is not
used, yielding a length of 641 aa for SmPDE9C compared to 756 and 758 for Smp_342020.1
and 2. In order to assess whether this splice variant was expressed in other lifecycle stages, or a
splice variant restricted to the adult worms, we completed PCR analysis using cDNA from
schistosomula, and juvenile and adult separated sex worms. A single band corresponding to
the size of the 3’ half of the extended sequence containing the catalytic domain insertion was
found in all stages (S2 Fig). We thus conclude that in both schistosomula, and in juvenile and
adult worms of both sexes, the same PDE is expressed.
There were two alleles of 1081 aa found for SmPDE11, which differed by 4 amino acids
from each other (none in the catalytic domain), with one sequence, SmPDE11-a1 having the
same amino acid sequence as the WBPS14 reference, Smp_179590.1. A matrix of amino acid
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sequence identity of the S. mansoni PDE sequences and examplar human and kinetoplastid
PDEs is given in S3 Fig; FASTA sequence of all the SmPDEs here reported is given in S1 File
(protein coding exons for all SmPDE genes) and S2 File (amino acid sequence).
Analysis of SmPDE expression levels in S. mansoni stages of mammalian
hosts
The level of expression of nine amplified and sequenced PDEs was investigated in separate
populations of S. mansoni developmental stages: schistosomula, separated male and female
juvenile (4 weeks old) and adult worms. Strikingly, there was a difference in expression level
between male and female worms, with male worms having higher expression levels for all
PDEs, in both mature and juvenile worms, with the single exception that expression of PDE9B
was not significantly different in 4-week old male and female worms (Fig 2). SmPDE4C is not
included in this study as it was not yet sequenced when the relative expression of the other
nine was determined.
The levels of expression of the PDEs were variable. SmPDE4A, SmPDE4B, SmPDE9C and
SmPDE11 displayed the highest levels of expression, which was particularly high in male juve-
nile and adult worms (relative abundance of between 60–140%, with the level of expression in
SmPDE4A adult males set at an abundance of 100). Relative abundance in female worms was
17–40%. The level of expression of all four was substantially lower in the schistosomula stage,
with relative abundance of ~40, 85, 75 and 15% respectively. Interestingly, SmPDE9C, which
we found to have an unusual catalytic domain insertion, appears to be one of the most highly
expressed S. mansoni PDEs, particularly in juvenile male worms. SmPDE1 and SmPDE9A are
hardly expressed in the stages that exist in the mammalian hosts (relative abundance of 0.22–
3.7% for SmPDE1 and 0.06–0.35% for SmPDE9A). SmPDE7var, SmPDE8 and SmPDE9B are
intermediately expressed, again being more highly expressed in male worms compared to
female, but in the range of 2–28%. These results are in close agreement with entries in the
online database schisto.xyz [37], which is the searchable interface for S. mansoni RNAseq
results from all life cycle stages and from the male and female gonads [38]. This database did
Fig 2. Expression levels of SmPDEs from the S. mansoni developmental stages that exist in mammalian hosts.
Expression of the cloned and sequence-confirmed SmPDEs in cDNA from schistosomula, male and female juvenile
worms, and male and female adult worms was determined by qRT-PCR and normalised to the level of expression of
the housekeeping gene COX1; the expression level of Sm4A in male adult worms was arbitrarily set as 100% and the
entire dataset (all life-cycle stages) expressed as a percentage thereof. cDNA was produced multiple times from Cairo
strain S. mansoni RNA samples; each bar represents the mean and SEM of 4–12 qPCR analyses.
https://doi.org/10.1371/journal.pntd.0008447.g002
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not have entries for SmPDE1 and SmPDE9A but did have entries for the two genes that we did
not obtain expression data for, SmPDE2 and SmPDE4C. Remarkably, only these two PDEs
were expressed more highly in female adults than male adults. This database also shows that
PDEs are poorly expressed in ovaries but many are robustly expressed in testes: PDEs 2, 4A,
4C, 7var, 9C and 11.
Complementation system in T. brucei
We developed a complementation system in the kinetoplastid parasite Trypanosoma brucei in
order to investigate the functional capabilities of the SmPDEs (Fig 3). The system is based on
the essentiality of a pair of tandemly arranged PDEs in T. brucei: TbrPDEB1 and TbrPDEB2
[39], and the simultaneous tetracycline-dependent expression of a single heterologous PDE to
compensate for the deletion of the essential genes.
To produce this system, first a single knockout cassette was introduced into T. b. brucei
(2T1 strain), by homologous recombination, introducing blasticidin resistance, and Herpes
Simplex Virus thymidine kinase (HSV-TK) that is necessary to later excise the antibiotic resis-
tance cassette using the loxP motifs [40] (Fig 3, contruct 2) (plasmid pHDK76). Next, a heter-
ologous (S. mansoni) PDE gene was introduced, with its expression under the control of
tetracycline, into the tagged rRNA locus of the T. b. brucei 2T1 cells [41], with the introduced
cassette also conferring hygromycin resistance (Fig 3, construct 3). The SmPDEs with which
complementation was attempted were SmPDE1, SmPDE4A, SmPDE4B, SmPDE8, SmPDE9A
and SmPDE11. In addition, both TbrPDEB1 and TbrPDEB2 were individually introduced
into this system as positive complementation controls (plasmid details given in S1 Table).
Following PCR confirmation of the successful introduction of the tet-controlled PDE gene,
we attempted to knock out the second pair of TbrPDEB1-B2 alleles using a puromycin-
HSV-TK cassette (pHDK82; Fig 3, construct 4). Following the generation of clonal populations
from these transfections, by limiting dilution, the clones were also grown in media without tet-
racycline, which should identify double null cell lines successfully complemented with the
Fig 3. Complementation strategy for S. mansoni PDEs in T. brucei. The TbrPDEB1 and TbrPDEB2 genes are in
tandem array (1), allowing replacement of one pair of alleles with a single antibiotic resistance gene by homologous
recombination (2). Into this single-KO strain, an exogenous gene is expressed under tetracycline (tet) control from the
rRNA locus, with an N-terminal tag consisting of the first 210 bp of TbrB1 (210 B1) to attempt to target the gene to the
flagellum (Luginbuehl et al. 2010), and a C-terminal GFP tag for expression analysis (3). The second pair of TbrB1/2
alleles can then be deleted if the exogenous gene can complement in the presence of tetracycline induction (4). Finally,
if tetracycline is removed from the media, the cells should die. The deletion cassettes were based on the work of Kim
et al. [40]. TK indicates HSV thymidine kinase.
https://doi.org/10.1371/journal.pntd.0008447.g003
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heterologous PDE, as the cell survival should depend on the tet-dependent expression of the
heterologous PDE (Fig 3, step 5). DNA was extracted for additional confirmation of loss of
TbrPDEB1-B2 by PCR.
We were able to successfully generate the control lines, expressing either TbrPDEB1-6Myc
or TbrPDEB2-6Myc, and used the cre-lox system [40] to remove the blasticidin and puromy-
cin antibiotic resistance cassettes (dKO+TbrPDEB1 and dKO+TbrPDEB2, respectively). With
the lines expressing SmPDE genes, only SmPDE4A was found to complement, with a single
clone that did not have either TbrPDEB1 or B2 and had the correct integration of the blastici-
din and puromycin resistance cassettes (dKO+SmPDE4A clone 1–3, S4 Fig). All other
SmPDEs attempted were unable to complement in this system, with rearrangements of the
TbrPDEB1-B2 locus being observed in order to integrate the antibiotic resistance cassettes.
We hypothesized that some of the PDEs may be cGMP specific and so not capable of com-
plementing in cAMP-dependent T. brucei. Alternatively their level of activity may be intrinsi-
cally lower than the native TbrPDEB1/B2 proteins; or perhaps the C-terminal GFP tag may
have interfered with their functionality. Moreover, the cellular localization of some of the
SmPDEs may have been wrong although all were N-terminally tagged with the first 70 aa of
TbrPDEB1, which should have resulted in the flagellar localization [42].
However, while this N-terminal sequence may be able to localize some proteins to the fla-
gellum, we found it was not in itself sufficient to do this for the S. mansoni PDEs, as verified by
fluorescence microscopy. For this purpose, the single KO cells, containing one TbrPDEB1/B2
allele plus the SmPDE construct, were stained with DAPI to highlight the nucleus and kineto-
plast, and the fluorescence of the GFP-tagged SmPDEs was also observed. It was found that the
GFP fluorescence in the SmPDE4A-expressing cells was much more intense, and much more
widely distributed throughout the cell body than that of the other SmPDEs (Fig 4). However,
even SmPDE4A, which clearly complemented the TbrPDEB1/B2 dKO, was not observed in
the flagellum, although it was present in the posterior end near the flagellar pocket; it is possi-
ble that the bulky GFP fusion is preventing flagellar localization.
Fig 4. Immuno-localization of SmPDEs after expression in T. brucei. T. brucei 2T1 cells from which a single
TbrPDEB1/B2 was deleted, and expressing either SmPDE1, SmPDE4A, SmPDE4B or SmPDE8, C-terminally
fused to GFP and N-terminally tagged with the first 70 aa of TbrPDEB1, were fixed, and stained with DAPI (blue
fluorescence) to reveal the nucleus and kinetoplast. The location of the GFP tag, and thus the position of the SmPDE
was revealed using antibodies against GFP (green fluorescence).
https://doi.org/10.1371/journal.pntd.0008447.g004
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Pharmacological evaluation of SmPDE4A-expressing T. brucei
In order to validate the complementation assay for its potential to be used for screening, we
selected a small set of known TbrPDEB1 inhibitors, related to the tetrahydrophthalazinone
inhibitor NPD-001, and tested them on the wild type as well as on the double KO comple-
mented with TbrPDEB1 or TbrPDEB2. Within this small set of compounds with a>200 fold
activity range on the wild type strain (41 nM—9.95 μM), we observed a correlation between
enzyme inhibiting potency and activity against the parasite, whether expressing both TbrPDEs
or just TbrPDEB1 (Fig 5A), which is in agreement with what we reported previously [30, 43].
This set of compounds shows consistently higher activity against the double knockout strain
expressing SmPDE4A (dKO+SmPDE4A) than against the strain expressing TbrPDEB1
(dKO+B1) or TbrPDEB2 (dKO+B2). Most interestingly, the dKO+SmPDE4A cells were highly
sensitized to compound NPD-356, with an EC50 of 5.2 ± 1.2 nM as opposed to 81 ± 32
(P<0.01, Student’s unpaired t-test) and 12 ± 3 nM (P<0.05) for the same cell lines expressing
TbrPDEB1 and TbrPDEB2, respectively. Similarly, NPD-001, NPD-226 and NPD-547 dis-
played both sub-micromolar activity against dKO+SmPDE4A (EC50 of 24 ± 3, 40 ± 4 and
480 ± 30 nM, respectively) as well as substantial selectivity over the T. brucei PDEs, particularly
TbrPDEB1 (P<0.01; Table 3). These results confirm that this complementation assay can be
used for screening compound libraries. The EC50s for each complementation line (TbrPDEB1,
TbrPDEB2, SmPDE4A) all exhibited excellent correlation with the EC50s for the wild-type
control (Fig 5B), and the same inhibitor rankings, showing that, as expected, all three enzymes
display very similar pharmacology. Indeed, both TbrPDEB1 and SmPDE4A have a high simi-
larity with human PDE4 [33, 44, 45] (S3 Fig) and as such each of these inhibitors also inhibits
hPDE4B1 (pEC50 range 8.4–10.3); it is likely that the successsful complementation by
SmPDE4A in T. b. brucei is at least in part due to its similarity to TbrPDEB1. The PDE3-selec-
tive compound Trequinsin, which has a low activity against TbrPDEB1 [46], was used as a neg-
ative control (EC50 > 25 μM for 2T1-WT and all complementation strains), whereas the EC50
values of all strains for the positive control, pentamidine, were not significantly different from
each other (Table 3).
The three most potent inhibitors (NPD-001, NPD-226 and NPD-356) were hypothesized to
exert their trypanocidal effects through inhibition of the respective PDEs expressed by each
cell line, given the differential effect on cell lines differing only by the PDE expressed. This was
tested by incubating dKO+SmPDE4A cells with a modest concentration of 2×EC50 of each
Fig 5. Analysis of the pharmacology of complementation cell lines. A. Correlation between the pIC50 of inhibition
of the purified enzyme TbrPDEB1 and pEC50s of the same compounds against either the parental (wild-type) cell line
2T1 (r2 = 0.50) or the double knockout strain complemented by TbrPDEB1 (r2 = 0.48). Both lines were found not to be
significantly non-linear by F-test (Prism 8.4, P>0.999). B. Correlation between the pEC50 values against 2T1 cells and
against the TbrPDEB1/B2 double knockout strain complemented by TbrPDEB1 (r2 = 0.993, slope 0.797, P<0.0001),
TbrPDEB2 (r2 = 0.967, slope 0.990, P<0.001) or SmPDE4A (r2 = 0.993, slope 1.148, P<0.0001).
https://doi.org/10.1371/journal.pntd.0008447.g005
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compound (or no compound, as control) for 2 h. As shown in Fig 6, there was indeed a signifi-
cant increase in the intracellular cAMP concentrations upon treatment with NPD-226, NPD-
356 and NPD-001, when compared to untreated control cells. These results demonstrate the
functional replacement of TbrPDEB1 and B2 with the SmPDE4A enzyme and show that such
cell lines are potential tools for the screening of compound libraries to identify selective PDE
inhibitors in a cellular system.
All the compounds were also tested for antischistosomal effects in vitro at a range of 5–
100 μM, displaying varying activities (S2 Table) that poorly correlate with their IC50 values
against SmPDE4A. For instance, NPD-001 was a highly active inhibitor of the enzyme
expressed in T. brucei, with IC50 0.10 ± 0.015 μM, but had no discernable impact on worm via-
bility, movement, coupling or ovipositing up to 50 μM; similarly NPD-227 had no effect on
worm viability but induced spastic contractions at 100 μM. In contrast, NPD-356 and NPD-
1014 displayed killing of male worms at concentrations of 25 and 50 μM, respectively, and
impacted ovipositing at 5 μM. Trequinsin had no effect on schistosome viability but did impact
worm coupling and ovipositing, especially at the higher concentrations.
SmPDE functionality in yeast
As functional complementation in T. brucei was not immediately successful with the majority
of SmPDEs attempted, we also utilized the previously published yeast complementation system
[47] in order to assess functionality of the SmPDE genes as phosphodiesterases. Complementa-
tion of the temperature sensitivity of the Saccharomyces cerevisiae strains PP5 and PM943
(both double deletion mutants for PDE1 and PDE2) was examined. S. cerevisiae lacking both
of its endogenous PDEs are viable but display a marked temperature sensitivity [48, 49] which
has successfully been utilized to validate heterologously expressed PDEs, complementing the
phenotype (e.g. [50–53]). After cloning the SmPDE genes into an S. cerevisiae expression vec-
tor, we tested complementation of the heat shock-sensitive phenotype of PP5 as described ear-
lier [54]. As is clear from the data in Fig 7A, besides TbrPDEB1 (positive control), SmPDE1,








EC50 (μM) RF(B1) RF(B2)
NPD-001 0.10 ± 0.015 0.165 ± 0.023 0.084 ± 0.018 0.024 ± 0.003 0.14��� 0.27��
NPD-029 9.95 ± 0.95 6.9 ± 0.6 6.1 ± 0.7 4.6 ± 0.4 0.67� 0.77�
NPD-226 0.16 ± 0.01 0.29 ± 0.11 0.082 ± 0.009 0.040 ± 0.004 0.13�� 0.48�
NPD-356 0.041 ± 0.004 0.081 ± 0.032 0.012 ± 0.003 0.0052 ± 0.0012 0.064�� 0.44�
NPD-547 1.72 ± 0.16 2.2 ± 0.6 0.93 ± 0.17 0.48 ± 0.03 0.22�� 0.52��
NPD-1014 7.4 ± 1.7 4.6 ± 0.9 4.7 ± 0.3 2.1 ± 0.1 0.45�� 0.45��
Trequisin 33.2 ± 0.9 25.8 ± 2.6 25.7 ± 2.4 34.5 ± 2.0 1.34 1.35
Pentamidine 0.0012 ± 0.0002 0.0016 ± 0.0005 0.0013 ± 0.0003 0.0016 ± 0.0003 1.00 1.24
EC50 values (μM) calculated by alamar blue assay for selected NPD compounds on T. brucei 2T1 cells and the same cells expressing inducible copies of SmPDE4A,
TbrPDEB1 or TbrPDEB2 instead of the normal TbrB1/2 tandem array (n = 3–9). The ratio of the EC50 value for the SmPDE4A-expressing cells and the EC50 value for
cells expressing either TbrPDEB1 or TbrPDEB2 is known as the relative resistance factor (RF(B1) and RF(B2), respectively); if >1 the compound displays higher activity
against the individual T. brucei PDE, if RF<1 the compound is more active against SmPDE4A. ND, not determined; NA, not applicable. Statistical difference between
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SmPDE4A, SmPDE8, SmPDE9A and SmPDE11 were able to complement the temperature
sensitivity of the pde1/2 deletion strain, indicative of cAMP degrading PDE activity. Comple-
mentation by SmPDE4A was anticipated as the purified protein was shown to possess cAMP
degrading activity in an earlier study [45] and we show in this study also complementation in
T. b. brucei. For the other complementing SmPDE genes, this is the first report highlighting
them as potential cAMP degrading enzymes. Expression of SmPDE4B, and SmPDE7var did
not complement the temperature sensitive phenotype in this experimental setup (Fig 7A).
Comparable results were obtained expressing the SmPDE genes in the PM943 strain, albeit
that the complementation by SmPDE1 was less pronounced in this system (pde1/2 deletion in
a different genetic background, S5 Fig).
Next, we analyzed the SmPDE expressing S. cerevisiae strains (PM943 background) in liq-
uid cultures allowing us to determine complementation of the temperature sensitivity under
less stringent conditions (Fig 7B). Decreasing both time of exposure and temperature, to 4 min
and 52 oC, respectively, still resulted in a marked temperature sensitivity in the control strain,
Fig 6. Analysis of intracellular cAMP after incubation of T. brucei bloodstream forms expressing SmPDE4A
(TbrPDEB1-/-, TbrPDEB2-/-) for 2 h with or without PDE inhibitor (each at a concentration of 2× their EC50
value). Each bar represents the average of three independent experiments (each analysed in duplicate) and SEM.
Statistical significance was determined relative to the untreated control cells using Student’s unpaired t-test; �, P<0.05;
��, P<0.01; ���, P<0.001.
https://doi.org/10.1371/journal.pntd.0008447.g006
PLOS NEGLECTED TROPICAL DISEASES Functional complementation of S. mansoni phosphodiesterases
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008447 July 30, 2020 13 / 29
which was complemented by the same SmPDE constructs that rescued the temperature sensi-
tivity in Fig 7A. Under these conditions SmPDE4B was still unable to complement the pheno-
type. However, expression of SmPDE7var also mediated a degree of complementation and
could therefore be included in the group of cAMP degrading PDEs from S. mansoni.
In conclusion, SmPDE1, SmPDE4A, SmPDE7var, SmPDE8, SmPDE9A and SmPDE11 dis-
play cAMP degrading activity. Complementation of the temperature sensitive phenotype of S.
cerevisiae double pde1/2 deletion strain was stronger for SmPDE1 and SmPDE4A-expressing
strains compared to the SmPDE8, SmPDE9A and SmPDE11-expressing strains, whereas
expression of SmPDE7var only weakly complemented the phenotype. No complementation
was observed when we expressed SmPDE4B. Differences in complementation between the var-
ious PDE expressing strains could be due to a lack of intrinsic catalytic activity, expression
level or subcellular localization of the different PDEs in the yeast model. Moreover, some
PDEs from S. mansoni would be expected to be cGMP-hydrolyzing enzymes, which is not
detectable in the S. cerevisiae cell model.
Expression and characterization of SmPDE4A, SmPDE8, and SmPDE11 in
S. pombe
The fission yeast S. pombe has been used as a host organism to express and characterize mam-
malian cAMP and cGMP-specific PDEs as well as to carry out high throughput screens for
inhibitors of these enzymes [55–59]. The SmPDE4A, SmPDE8, and SmPDE11 genes were
cloned into an expression vector and integrated into the S. pombe genome to create strains
that stably express these enzymes. SmPDE8 and SmPDE11 had displayed rather weak comple-
mentation in the S. cerevisiae system, and it was appropriate to further verify that cAMP was
their main substrate; SmPDE4A as the gene giving the strongest complementation in both the
T. brucei and S. cerevisiae systems, was included as positive control.
After introduction of the three S. mansoni genes into S. pombe, the PDE activity was
assessed using a 5-fluoro-orotic acid (5FOA) growth assay, which reflects PKA-mediated
Fig 7. Complementation of temperature sensitivity by SmPDEs. A) Temperature sensitivity of the pde1/2 deletion
strain PP5 is complemented to various extents by SmPDE1, SmPDE4A, SmPDE8, SmPDE9A and SmPDE11,
respectively. PP5 transformed with TbrPDEB1 was taken along as positive control. Duplicate patches of recombinant
yeast strains were subjected to heat shock (55˚C for 15 min) or control conditions (30 oC) and were then grown at
30˚C for 1 day. (B) Heat shock complementation in liquid culture. Growth of pde1/2 deletions strain (PM943)
expressing SmPDEs was analyzed after exposure to an increased temperature (4 min, 52 oC) or in control condition.
Growth (OD600) was examined over 72 h. The resulting growth curves were analyzed for onset of the exponential
phase. Comparison of the growth curves of cultures exposed to heat shock and control conditions indicate that
SmPDE4B are unable to complement the phenotype (a delay in onset of exponential growth compared to the control,
set at 100% (red dotted line). In this assay, TbrPDEB1 (positive control (in green)), SmPDE1, SmPDE4A, SmPDE8,
SmPDE9A and SmPDE11 and SmPDE7var display a faster onset of the exponential growth after a high temperature
challenge compared to the control condition.
https://doi.org/10.1371/journal.pntd.0008447.g007
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transcriptional repression of an fbp1-ura4 reporter gene. As seen in Fig 8A, cells that lack any
PDE activity respond to low micromolar concentrations of cAMP or cGMP to activate PKA
and promote growth. A strain expressing SmPDE8 responds to cGMP in a manner similar to
that of a strain with no PDE, but requires significantly more cAMP to promote growth, consis-
tent with it possessing a cAMP-hydrolyzing PDE but having almost no activity against cGMP.
The SmPDE11-expressing strain shows a greater shift in the amount of cGMP relative to
cAMP needed to promote growth when compared to the strain lacking PDE activity, consis-
tent with SmPDE11 being a dual-specificity enzyme that is more active on cGMP than on
cAMP (Fig 8B). Finally, the SmPDE4A strain displays the highest PDE activity, such that even
9 mM cAMP is not sufficient to fully activate PKA (Fig 8C). SmPDE4A also appears to confer
considerable insensitivity to cGMP to suggest that it is a dual specificity PDE, albeit with a sig-
nificant preference for cAMP over cGMP. An overview of all SmPDEs and their complementa-
tion in the different yeast strains is given as S3 Table.
Fig 8. 5FOA-resistant growth of S. pombe strains expressing SmPDE4A, SmPDE8, and SmPDE11 in response to
exogenous cAMP or cGMP. 5FOA-resistant growth is due to PKA-mediated repression of an fbp1-ura4 reporter in
these strains. A) Growth response curves to varying doses of cAMP or cGMP in strains expressing SmPDE8 as
compared to a strain devoid of PDE activity. B) As frame A, for SmPDE11. C) As frame A, for SmPDE4A. Values
represent means and standard errors for three to five independent assays for each strain.
https://doi.org/10.1371/journal.pntd.0008447.g008
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Discussion
The shortcomings of praziquantel, including ineffectiveness against immature worms, failure
to achieve full clearance, and reports of diminishing efficacy, make the case that alternative
treatment options or at a minimum an early drug discovery pipeline for schistosomiasis drugs
is essential. Yet, ironically, the virtues of praziquantel—non-toxic, easy to administer and,
above all, available and cheap enough for mass-administration programs—make drug discov-
ery programmes for this neglected disease highly unlikely. As argued by Ramamoorthi et al.
this logically leads towards the repurposing of existing drugs and compound libraries as an
economical short-cut towards new treatments of schistosomiasis, as reflected in the fact that
almost all recent clinical trials against schistosomiasis have been conducted with existing drugs
against other neglected parasitic diseases [60, 61].
We have long argued [62, 63] that highly conserved proteins such as cyclic nucleotide phos-
phodiesterases (PDEs) potentially make excellent drug targets in neglected diseases because of
the shortcuts in development time and money this approach affords, drawing as it does on the
wealth of pharmacological, genetic, structural and toxicological information available on PDE
inhibitors for the treatment of conditions as diverse as heart failure [64], erectile dysfunction
[65] and chronic obstructive pulmonary disorder (COPD) [66]. The exploration of PDEs as
potential drug targets for schistosomiasis is in keeping with similar efforts to develop inhibitors
for the Schistosoma equivalents of targets for cancer [67, 68], hypercholesterolemia [69] or car-
diovascular disease [70]. In this strategy the design of the final inhibitors will rely on a combi-
nation of high-throughput screening of targeted compound libraries and structure-guided
final optimization to achieve the necessary selectivity.
We have recently published a first phenotypic screening of a PDE-inhibitor-enriched
library and found that many of the compounds displayed anti-schistosomal effects such as
worm survival, ovipositing and movement—with male worms being much more affected than
female worms [34]. Several compounds were tested in mouse models of schistosomiasis and
displayed partial clearance of worm and egg burdens. Similarly, Conor Caffrey’s group
screened a library of benzoxaboroles for antischistosomal activity and found that many of the
most active compounds were submicromolar inhibitors of human PDE4B2 [33]. They went on
to identify by BLAST-P searches four S. mansoni PDE sequences: SmPDE4A-C (confirmed in
the current manuscript) and SmPDE4D, which we here propose to rename SmPDE8 based on
its phylogenetic alignment with hPDE8B, and concluded that SmPDE4A is likely to mediate
the effects of the benzoxaboroles under study, in part via expression of SmPDE4A in pde4-de-
ficient C. elegans. Further inhibitors of SmPDE4A were recently identified by in silico screen-
ing of PDE inhibitors against a homology model of SmPDE4A [45] and the PDE4 inhibitor
roflumilast was investigated for activity against S. mansoni in vitro and in a mouse model [71].
In this paper we report the first cloning, from cDNA, of 10 of the 11 PDE ORFs that could
be identified in the S. mansoni genome. These 10 sequences appear to be full-length and poten-
tially functional phosphodiesterases with intact catalytic domains. Phylogenetic analysis
assigned 8/10 closely to human clades, facilitating the S. mansoni PDE nomenclature. In the
two cases where there was no unambiguous assignment to a hPDE clade, a protein BLAST
identified hPDE7 and hPDE11, respectively, as the top hits, and the genes were named
SmPDE7var and SmPDE11 accordingly. The S. mansoni strain from which we derived the
cDNA was heterozygous for SmPDE4B, SmPDE7var, SmPDE9B and SmPDE11, and homozy-
gous for the other 6 ORFs. More importantly, we found significant differences such as exon
extensions, extra exons and insertions in several of the cloned ORFs. The sequences given in
the Long et al. [33] paper, being the predicted database sequences of the time, appear to be
incorrect or incomplete, although it is possible the differences are attributable to strain
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differences. Among the significant differences with the published genome (Puerto Rico strain) we
observed that our experimental transcript of SmPDE8 was 270 aa shorter than the WBPS14 entry,
and had an extended exon 7, replacing exon 8 of Smp_044060. Multiple significant differences
were also observed between our sequence of SmPDE9B and the reference entry Smp_342020.
Most of the other SmPDEs here reported displayed smaller differences with the reference entries.
We found no evidence that the significant differences in SmPDE8 and 9C could be splice variants,
as the sequences were separately amplified from cDNA from schistosomula, juvenile, adult, male
and female worms, always resulting in products of very similar length.
In order to assess which of these sequences encode for genuine 3’,5’-cyclic nucleotide phos-
phodiesterases, a cellular complementation system was constructed in a T. brucei pdeB1+/-/
pdeB2+/- clonal line, where the SmPDE was expressed conditionally under control of a tetracy-
cline-inducible promotor. Successful complementation in this system enabled the deletion of
the second TbrPDEB1/B2 allele while retaining normal growth; upon withdrawal of tetracy-
cline from the medium the cells would die. This system does not only unambiguously demon-
strate cAMP catalytic activity of the heterologous PDE, it is ideal for the screening of inhibitors
against the expressed PDE in a cellular system that is easily grown in any reasonable quantity
and highly amenable to high-throughput screens in suspension cultures in multi-well plate for-
mats. SmPDE4A, expressed in this system, complemented very well for the deletion of the
TbrPDEB1/B2 alleles, and was subjected to an initial proof-of-concept screen with a limited
number of PDE inhibitors, performed in parallel with cell lines expressing TbrPDEB1 or
TbrPDEB2 only under the same tetracycline-dependent promotor. The strongest inhibitor
identified from this limited series was NPD-356, which displayed an EC50 of just 5.2 ± 1.2 nM
against the SmPDE4A-expressing cell line, significantly lower than the corresponding EC50
values of the clones expressing TbrPDEB1 or TbrPDEB2. Other inhibitors with significant
preference for the Schistosoma PDE over T. brucei PDEs included NPD-001 and NPD-226; all
three were shown to induce elevated intracellular cAMP levels in T. brucei. Thus, this comple-
mentation approach allows the parallel screening of multiple cell lines, each dependent on
(and different by only) a single PDE, allowing rapid comparison of relative potency for each
inhibitor, as well as immediate verification of on-target action in a eukaryotic cell through
the measurement of intracellular cAMP. However, the complementation of some SmPDEs in
this system was not immediately successful, owing to the requirement that a significant
cAMP-PDE activity be present in the flagellum. Although we engineered the 70 N-terminal
amino acids of TbrPDE-B1 onto the complementation constructs of all SmPDEs, which should
have ensured this [42], it is possible that the tagging with GFP prevented the correct localiza-
tion. Meanwhile, further complementation, with the principal aim of demonstrating catalytic
activity rather than inhibitor screening, progressed via expression in the budding yeast Saccha-
romyces cerevisiae and the fission yeast Schizosaccharomyces pombe.
Utilizing the temperature sensitivity of S. cerevisiae pde1/2 double deletion strains, we have
been able to confirm cAMP hydrolyzing activity in several of the SmPDEs heterologously
expressed in this cell system. Particularly robust complementation was observed when express-
ing SmPDE1 and SmPDE4A, which may allow the further biochemical and pharmacological
characterization of these PDEs in yeast extract, as has recently been done for Giardia lamblia
PDE1 [53]. Alternatively, expression in yeast, bacteria or insect cells, and subsequent isolation
and purification may be feasible to further characterize the purified enzymes biochemically
(enzyme kinetics and substrate specificity) and pharmacologically. Specific pharmacological
profiles of the SmPDEs may allow determination of the PDE(s) that can be therapeutically tar-
geted to prevent or cure schistosomiasis. Evidence of more modest cAMP PDE activity was
also observed with SmPDE8, SmPDE9A and SmPDE11, whereas SmPDE4B was inactive in
this system.
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Both the T. brucei and S. cerevisiae complementation systems only allow complementation
by cAMP phosphodiesterases but cannot function with cGMP-specifc PDEs; however the S.
pombe system is able to detect both cAMP and cGMP degradation by the heterologously
expressed enzyme and we used it to demonstrate PDE activity of SmPDE4A, SmPDE8 and
SmPDE11. Using a 5FOA growth assay that reflects PKA activity, strains expressing these
three enzymes (while lacking endogenous adenylyl cyclase and PDE activity) were shown to
require more exogenous cAMP and/or cGMP to activate PKA and promote 5FOA-resistant
growth than is required for a strain devoid of PDE activity. Similar to mammalian PDE8A and
PDE11A when expressed in this system [56, 57], SmPDE8 selectively acts on cAMP, while
SmPDE11 shows a preference for cGMP over cAMP. In addition, SmPDE4A is significantly
more active than either SmPDE8 or SmPDE11, similar to what was seen for mammalian PDE4
enzymes relative to PDEs from 9 other PDE families [57, 58]. However, SmPDE4A appears to
display a considerable activity against cGMP in addition to a substantially higher activity
against cAMP.
In conclusion, we report here the naming and cataloguing of 11 predicted Schistosoma
mansoni PDEs and the cloning of 10 of them. Confirmation of cyclic nucleotide degradation
was obtained for SmPDE1, SmPDE4A, SmPDE8, SmPDE9A and SmPDE11, and to a lesser
extent SmPDE7var. SmPDE11was mostly specific for cGMP and SmPDE4A displayed consid-
erable dual activity. An innovative complementation system in T. brucei was shown to allow
rapid and comparative inhibitor screening of multiple PDEs in a standardized cellular system.
We believe this is an important contribution in developing a new drug discovery pipeline for
schistosomiasis based on targeting conserved, druggable elements in its regulatory systems.
Materials and methods
Identification of potential SmPDE genes
The S. mansoni genome (ftp 1) and protein (ftp 2) sequence databases provided by
WormBase/ParaSite (WBPS14) [72. 73] were searched for the presence of class I PDEs using
the HMMER software package (version 3.1b2) [74]. The profile hidden Markov model
(HMM) was generated from a curated multiple sequence alignment of 24 catalytic domain
sequences comprising one member of all 11 human PDE families as well as characterized
PDEs from protozoan parasites, Drosophila melanogaster, Caenorhabditis elegans and Saccha-
romyces cerevisiae as described earlier [53]. The searches against the genome database for
detecting PDE sequences not present in the current/existing gene models were done using two
different approaches: (1) The genome sequence was split into fragments of 1500 bases that
overlap by 750 bases and all fragments were translated into amino acid sequences (all 6 reading
frames); (2) all open reading frames with a length of at least 90 nucleotides were translated into
amino acid sequences. The thus generated datasets were searched using the PDE profile
HMM. Search parameters are given in S3 File. Hit sequences with an E-value between 0.1 and







Schistosomula, juvenile and adult Schistosoma mansoni worms recovered 3, 4 and 6 weeks
post infection of mice with 70 S. mansoni cercariae were obtained from the Schistosome
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Biology Supply Center (SBSC) of the Theodor Bilharz Research Institute (TBRI), stabilized
using RNAlater (Invitrogen, ThermoFisher) and sent for processing from TBRI to the Univer-
sity of Glasgow. RNA was extracted from worms and schistosomula using a Macherey Nagel
Nucleospin RNA extraction kit, and from this, cDNA was produced using Superscript III
reverse transcriptase (ThermoFisher), all following manufacturer’s instructions. Genomic
DNA was prepared from isolated worms at TBRI and shipped to University of Glasgow.
Bloodstream-form T. b. brucei Lister 427 2T1 strain [75] and its derivatives were main-
tained in HMI-11 medium [76], at 37˚C in a 5% CO2 atmosphere, exactly as described [77].
Amplification of PDEs
Depending on the arrangement of the exons, the first 1–3 and last 1–2 exons of all 11 S. man-
soni PDEs were amplified from genomic DNA, using primers upstream or downstream of the
predicted exons and a primer in the predicted exon (see S4 Table for primers and details), and
a proof reading polymerase (Phusion; NEB, Hitchen, UK). This sequence information was
used to design primers to amplify the complete coding sequence for each PDE from mixed
adult worm cDNA, again using Phusion polymerase. Some PDEs were amplified in two sec-
tions due to size/primer incompatibility (S4 Table). These strategies were successful for all pre-
dicted SmPDE ORFs except SmPDE2. All sequences generated were submitted to GenBank
(Table 1). cDNA produced from different S. mansoni life-cycle stages (schistosomula; juvenile
female/male worms; adult female/male worms) were used in attempts to amplify the complete
SmPDE2 or sections thereof, alongside attempts to amplify individual exons from genomic
DNA. All amplified fragments were ligated into the pGEMT-Easy subcloning vector (Pro-
mega, Southampton, UK) and Sanger sequenced by Source BioScience (Nottingham, UK). It
should be noted that a recently launched online resource schisto.xyz [37] lists SmPDE2 as
detectable by RNAseq, and expressed particularly in adult worms (SmPDE2).
Phylogenetic analysis
The sequences of the SmPDEs were compared to representative members of the eleven human
PDE families; the sequences of these were taken from the UniProt database [78], taking the top
human hit for each PDE number (http://www.uniprot.org/; hPDE1C - Q14123; hPDE2A3—
O00408; hPDE3A - Q14432; hPDE4B1—Q07343; hPDE5A1—O76074; hPDE6A - P16499;
hPDE7B - Q9NP56; hPDE8B - O95263; hPDE9A - O76083; hPDE10A - Q9Y233; hPDE11A -
Q9HCR9). The in-house sequences for SmPDEs were used where available while of necessity
using the GeneDB sequences for SmPDE2. In order to derive a systematic naming convention
a phylogenetic tree was constructed, using the Maximum Likelihood Tree function of
MEGA6, with 500 bootstrap replications and the default parameters ([79]; https://www.
megasoftware.net/). This was complemented with BLAST searches using the SmPDE protein
sequences to compare naming of orthologues in S. haematobium found using the WormBase
Parasite database ([73]; https://parasite.wormbase.org/Schistosoma_haematobium_
prjna78265/Info/Index?db=core).
qRT-PCR expression profiling
The expression profile of each of the 9 amplified S. mansoni PDEs was generated from five sep-
arate cDNA pools: schistosomula, juvenile female and male worms, adult female and male
worms. Primers used are given in S4 Table. GoTaq qPCR master mix (Promega) was used to
amplify the fragments, using an Applied Biosystems 7500 Real Time PCR System, following
manufacturer’s instructions. The differences in expression levels were calculated relative to the
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S. mansoni COX-1 gene as control (primers from [80]), previously shown to be highly and
constitutively expressed in various lifecycle stages [81].
Trypanosome plasmid construction and transfection
Each amplified SmPDE was resynthesized by BaseClear (Leiden, The Netherlands) with Trypa-
nosoma brucei-optimized codon usage. The codon optimization was completed using the Inte-
grated DNA Technologies tool (https://www.idtdna.com/CodonOpt) with manual checking to
remove unwanted restriction sites from the sequences.
For expression in T. brucei the genes were inserted into the tetracycline-inducible pRPa-
series of vectors [41] for expression from a tagged rRNA locus. TbrPDEB1 and TbrPDEB2
were inserted into the pRPaix6Myc vector containing a C-terminal 6Myc tag, whilst the SmPDEs
were inserted into the pRPaixGFP vector, giving proteins with C-terminal Green Fluorescent
Protein (GFP) tags. In addition, the first 210 bp of TbrPDEB1 were amplified from T. brucei
Lister 427 genomic DNA and added to the N-terminal end of all SmPDE genes to drive flagel-
lar localization. This region has been previously shown to be necessary and sufficient for the
targeting of TbrPDEB1 to its essential flagellar location [42].
For the knockout of the TbrPDEB1-B2 locus, constructs were generated using the cre-lox
null vectors developed by George Cross [40], which contain an antibiotic resistance gene fused
to the Herpes Simplex Virus thymidine kinase (HSV-TK) gene, flanked by loxP sites to allow
removal of the resistance cassette by cre-recombinase. The HSV-TK gene allows for selection
of cells in which the cre-lox process has successfully removed the antibiotic cassette, as the
cells regain resistance to ganciclovir when the HSV-TK gene is removed. To integrate the anti-
biotic-resistance cassettes, a 321 bp region of the 5’ UTR of TbrPDEB1 and a 560 bp region of
the 3’ UTR of TbrPDEB2 was introduced on either side of the antibiotic-resistance gene in
order to simultaneously knock out the in-tandem TbrPDEB1 and TbrPDEB2 ORFs. Con-
structs containing blasticidin-HSV-TK and puromycin-HSV-TK resistance cassettes were
used to sequentially knock out the two tandemly arranged alleles.
All plasmids were checked by Sanger Sequencing (Source BioScience) and linearized by
restriction digest prior to transfection. 2T1 strain of Lister 427 T. brucei parasites were washed
into Tb-BSF buffer for transfection of the desired cassette with program X-001 using an
Amaxa Nucleofector as described [82]. Transfectants were grown and cloned out, by limiting
dilution, in standard HMI-11 medium containing the appropriate antibiotics (depending on
the transfection: hygromycin at 2 μg/ml, blasticidin at 5 μg/ml, puromycin at 0.5 μg/ml, phleo-
mycin at 0.5 μg/ml and tetracycline at 1 μg/ml). Correct integration of the expression/knock-
out cassettes was verified by PCR (primers in S4 Table). A complete list of T. brucei vectors
used is given in S1 Table).
Immunofluorescence
Fluorescent imaging of tagged cell lines was performed as previously described [83] with slight
modifications. Briefly, the different cell lines were cultured to a concentration of 1×106 cells/
ml and 1 ml was taken and centrifuged at 1000 × g in a microfuge. The media was removed
and pellet washed with phosphate-buffered saline (PBS); excess PBS was taken off, pellets
resuspended in 20 μl PBS and spread on microscopic slides. The slides were air-dried, fixed in
4% formaldehyde/PBS for 15 min and rinsed in PBS three times before the slides were treated
with 0.1% Triton X-100 (Sigma-Aldrich) in PBS for 5 min with gentle shaking in order to per-
meabilize the cells. Blocking of non-specific binding was performed in 1% bovine serum albu-
min (BSA)/PBS for 30 min after which the slides were incubated with primary antibody (Anti-
GFP antibody) diluted 1:2000 in 1% BSA/PBS for 1 h at room temperature (RT) on a shaker
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(speed 12–15). After incubation with primary antibody, slides were washed thrice with PBS for
10 min and then incubated with secondary antibody (Alexa Fluor 594 goat anti-rabbit IgG
(H+L); Life Technologies) diluted 1:1500 in 1% BSA/PBS at RT for 45 min. The slides were
rinsed three times in PBS for another 10 min, soaked in 70% ethanol for 1 min followed by
100% ethanol for 1 min, all at RT. Finally, the slides were air-dried, rehydrated in PBS and
were mounted in a drop of Vectashield Mounting medium containing 4,6-diamidino-2-phe-
nylindole (DAPI; Vector Laboratories Inc.). Cells were visualized using oil immersion at 100×
magnification under UV light using a Delta Vision Core microscope (Applied Precision) and
SoftWorkX software. Cells were viewed using Brightfield, DAPI (λ = 405/435 nm) and FITC
(λ = 488/520 nm) filters.
Trypanosome drug sensitivity assays
Drug sensitivities were assessed using a modified version of the alamar blue assay described
previously [84, 85]. Briefly, test drugs were serially diluted in 100 μl of complete HMI-11
media across two rows of a white 96-well plate (Greiner, Stonehouse, UK). Bloodstream-form
trypanosome cultures were diluted in HMI-11, and 100 μl was added to all wells to give a final
cell density of 1 × 105 trypanosomes/ml. Plates were incubated for 48 h at 37˚C/5% CO2, prior
to the addition of 20 μl of 5 mM resazurin sodium salt (Sigma-Aldrich, Gillingham, UK) in
PBS, pH7.4. Plates were incubated for a further 24 h in the same conditions, before fluores-
cence was measured using a FLUOstar Optima fluorimeter (BMG Labtech, Aylesbury, UK)
with excitation and emission filters of 544 nm and 590 nm, respectively. The 50% effective con-
centrations (EC50) were calculated using the equation for a sigmoidal curve with variable slope
of Prism 5.0 (GraphPad). All EC50 values were determined at least three times independently.
Potential PDE inhibitors
All of the potential inhibitors tested on SmPDE4A-expressing cell lines were prepared at the
Free University of Amsterdam (VUA; Amsterdam The Netherlands), University of Antwerp
(UA; Antwerp, Belgium) and Centro de Investigaciones Biológicas (CIB-CSIC; Madrid, Spain)
and have a purity�95% by HPLC. A list including structures and references is included as S5
Table.
Quantification of intra- and extra-cellular cAMP
The intra- and extra-cellular concentration of cAMP in bloodstream form T. brucei brucei cell
lines, upon incubation with various phosphodiesterase inhibitors, was measured as described
previously [86], using the Cyclic AMP ELISA kit (Cayman Chemicals, Cambridge Bioscience,
Cambridge, UK). Samples were taken in duplicate, and all assays were conducted indepen-
dently at least three times.
Yeast strains, plasmid construction and transformation
The SmPDE gene sequences were cloned into a yeast (S. cerevisiae) expression vector (pJB341;
YCplac111-based, sc, LEU2, PGK constitutive promoter cloned into the EcoRI and BamHI
sites) using the appropriate restriction sites. Cloning was done directly from the T. brucei-opti-
mized DNA sequences in pUC57-Amp (Baseclear, Leiden, NL) or after re-PCR from the syn-
thesized genes and cloning in an intermediate vector. SmPDE4A_FL was amplified with 5’
BamHI and 3’ SphI sites and cloned into intermediate vector pSSS05 (pOPINF). SmPDE4B_
FL was amplified with 5’ BamHI and 3’ XbaI sites and cloned into intermediate vector
pSSS013 (pFastBac HT B). SmPDE9A_FL was amplified with 5’ BamHI and 3’ SphI sites and
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cloned into intermediate vector pSSS014 (pFastBac HT B). SmPDE9B_FL was amplified with
5’ BamHI and 3’ XhoI sites and cloned into intermediate vector pSSS011 (pFastBac HT B).
SmPDE1_FL was amplified with 5’ BamHI and 3’ SphI sites, cloned into intermediate vector
pSSS012 (pFastBac HT B). Both SmPDE8_FL and SmPDE11 were cloned directly using the 5’
BglII -SphI 3’ sites in the synthesized gene. Transformation of the constructs into the PDE-
deficient S. cerevisiae strains PP5 (MATa leu2,112 ura3-52 his3-532 his4 cam pde1::URA3
pde2::HIS3) [51] and PM943 (W303-1A pde1Δ pde2Δ; MATa leu2-3,112 ura3-1 trp1-92 his3-
11, 15 ade2-1 can1-100, GAL SUC mal pde1::TRP1 pde2::URA3) [49] was carried out as
described previously [47].
Complementation of the heat shock-sensitive S. cerevisiae pde1/2 double
deletion strain
The heat shock-sensitive phenotype of the PDE-deficient S. cerevisiae strains PP5 and PM943
was utilized to analyze the functionality of heterologously expressed SmPDEs. These assays
were carried out as described [47]. Transformed yeast strains were streaked onto SC-leu plates
(selective medium lacking leucine) and grown for 2 days at 30˚C. The colonies were then rep-
lica-plated onto YPD plates prewarmed to 55˚C, and were incubated for another 15 min at
55˚C. Plates were then cooled to room temperature and incubation was continued at 30˚C for
18–36 h. Alternatively, complementation of the heat shock-sensitive phenotype of the pde1/2
deletion strain (PM943) was measured in liquid cultures, for which a fresh colony was used to
inoculate 5 ml of SC-leu medium. The culture was grown for 54 h at 30 oC while shaking (190
rpm) and then diluted to OD600 1.0 in SC-leu medium (500 μl volume). Heat shock was per-
formed in Eppendorf tubes; 150 μl culture was exposed to 52 oC for 4 min (in water bath) and
subsequently cooled on ice (1.5 min). Heat-shocked and control cultures were diluted 1:10 in
YPD and analysis of growth (OD600) was made in 96 wells plates (clear, flat bottom; Greiner)
in a plate reader (Infinite F200, Tecan) pre-heated to 30 oC. Data was captured in the Magellan
software (Tecan) and analyzed using Excel (MS Office 2016) and Prism 8.0 software (Graph-
Pad). Complementation was determined by comparing the time to reach early-exponential
phase in control conditions and after exposure to increased temperature.
Construction of Schizosaccharomyces pombe strains expressing SmPDE4A,
SmPDE8, and SmPDE11
The genotypes of S. pombe strains used in this study are presented in S6 Table. Cells were cul-
tured at 30 ºC in YES-rich (yeast extract medium with supplements) or EMM-defined media
as described previously [87]. SmPDE4A, SmPDE8, and SmPDE11 were cloned into the S.
pombe expression vector pNMT1 [88] by PCR amplification of the open reading frames using
custom oligonucleotides (S7 Table) designed to facilitate insertion of the genes into EcoRI-
digested pNMT1 by gap repair transformation of strain SP578 to leucine prototrophy [89, 90].
SP578 carries a loss-of-function mutation in the S. pombe cgs2 PDE gene and is a homothallic
(h90) strain, such that cells within a single colony are capable of mating with each other. How-
ever, the cgs2-2 mutation eliminates endogenous PDE activity and the elevated cAMP levels
activate PKA to prevent cells from mating within the colony. Transformant colonies were
screened by iodine vapor staining in order to detect colonies that acquired an active PDE as
this would reduce cAMP levels to restore mating. Plasmids from these colonies were rescued
into E. coli [91] and DNA sequencing was used to identify clones carrying wild type alleles of
these PDE genes. These plasmids were then linearized by BlpI digestion, which cuts uniquely
within the ars1 region of pNMT1 and S. pombe strain CHP1265 was transformed to leucine
prototrophy, followed by screening via plasmid loss to detect transformants carrying the
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plasmids integrated into the ars1 chromosomal locus. Subsequent crosses confirmed that these
plasmids were integrated, and they were used to construct strains lacking endogenous adenylyl
cyclase and PDE activity to allow for characterization of SmPDE4A, SmPDE8, and SmPDE11
with regard to catalytic activity against cAMP and cGMP.
S. pombe 5FOA growth assays to examine substrate specificity of
SmPDE4A, SmPDE8, and SmPDE11
Strains CHP1207 (no PDE), CHP2344 (SmPDE8) and CHP2346 (SmPDE11) were grown to
exponential phase (~107 cells/ml) in EMM medium containing 10 mM cAMP to repress tran-
scription of the fbp1-ura4 reporter used to reflect PKA activity. As PDE4A possesses a high
level of activity against cAMP, strain CHP2345 (PDE4A) was grown to exponential phase in
EMM medium containing 5 mM cGMP and 5 μg/ml thiamine (to reduce transcription of
PDE4A from the nmt1 promoter [92]). Cells were washed with 5FOA medium [93] to remove
exogenous cAMP or cGMP and plated as 50 μl cultures at either 105 cells/ml (CHP1207) or
3×105 cells/ml (CHP2344, CHP2345, CHP2346) in 384-well clear-bottom plates with various
concentrations of either cAMP or cGMP. Triplicate wells were averaged for each data point
and OD600 was measured after 48 h incubation at 30 ºC. Each strain was assayed 3–5 times.
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